Crinetics Pharmaceuticals, Inc.
CRNX
Peringkat dalam Saham
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Harga Saham
$84.95
Terakhir disinkronkan: 2026-09-01
Kapitalisasi Pasar
$9.00B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
98.25%
Negara
US
Perdagangan Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Jumlah saham beredar untuk Crinetics Pharmaceuticals, Inc. (CRNX)
Jumlah saham beredar per June 2026: 105.56M
Menurut laporan keuangan terbaru dan harga saham Crinetics Pharmaceuticals, Inc., jumlah saham beredar saat ini adalah 105.56M. Pada akhir December 2023, perusahaan memiliki 58.07M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Crinetics Pharmaceuticals, Inc. (CRNX) dari 2016 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 105.56M | 30.67% |
| 2024 | 80.78M | 39.11% |
| 2023 | 58.07M | 11.71% |
| 2022 | 51.98M | 35.24% |
| 2021 | 38.44M | 26.23% |
| 2020 | 30.45M | 25.95% |
| 2019 | 24.18M | 99.10% |
| 2018 | 12.14M | -12.51% |
| 2017 | 13.88M | 0.00% |
| 2016 | 13.88M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 140.53% |
US
|
|
| 396.00M | 275.14% |
US
|
|
| 478.91M | 353.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -41.09% |
NL
|
